GlassScriptPhysician profile
Christopher A Baltes
NPI 1992090971
$1,202.67
in general payments reported to CMS, 2019-2025
19 companies · $36.84 in 2025
The $36.84 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $78.12 · 2021: $252 · 2022: $89.53 · 2023: $166 · 2024: $347 · 2025: $36.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $268.00 | 2019-2025 | Wegovy |
| Pfizer INC. | $126.18 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $124.38 | 2019-2024 | Breztri, Farxiga |
| Lilly USA, LLC | $113.50 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $107.02 | 2021-2024 | |
| Glaxosmithkline, LLC. | $69.76 | 2020-2024 | Trelegy Ellipta, Shingrix |
| Axsome Therapeutics, INC. | $59.68 | 2023-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $58.52 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.16 | 2019-2022 | |
| Amgen INC. | $43.50 | 2021-2023 | Prolia, Evenity |
| Sanofi-Aventis U.S. LLC | $33.93 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.75 | 2021 | |
| Exact Sciences Corporation | $29.26 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $18.67 | 2023 | Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $16.85 | 2024 | Eliquis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $16.58 | 2023 | Nuedexta |
| Genentech USA, INC. | $16.17 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.42 | 2024 | Quviviq |
| Merck Sharp & Dohme LLC | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Baltes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.